Mackenzie Financial Corp raised its position in GlaxoSmithKline plc (NYSE:GSK) by 39.6% during the 4th quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The firm owned 13,942 shares of the pharmaceutical company’s stock after buying an additional 3,956 shares during the quarter. Mackenzie Financial Corp’s holdings in GlaxoSmithKline were worth $495,000 at the end of the most recent quarter.
A number of other hedge funds have also recently added to or reduced their stakes in the business. Hotchkis & Wiley Capital Management LLC increased its holdings in GlaxoSmithKline by 7.3% in the 3rd quarter. Hotchkis & Wiley Capital Management LLC now owns 8,416,927 shares of the pharmaceutical company’s stock valued at $341,727,000 after buying an additional 569,600 shares during the period. NWQ Investment Management Company LLC grew its holdings in shares of GlaxoSmithKline by 9.4% during the 3rd quarter. NWQ Investment Management Company LLC now owns 2,728,458 shares of the pharmaceutical company’s stock valued at $110,775,000 after purchasing an additional 233,689 shares during the last quarter. Brandes Investment Partners LP grew its holdings in shares of GlaxoSmithKline by 6.1% during the 4th quarter. Brandes Investment Partners LP now owns 2,262,946 shares of the pharmaceutical company’s stock valued at $80,267,000 after purchasing an additional 130,182 shares during the last quarter. Ameriprise Financial Inc. grew its holdings in shares of GlaxoSmithKline by 7.1% during the 3rd quarter. Ameriprise Financial Inc. now owns 1,855,142 shares of the pharmaceutical company’s stock valued at $75,028,000 after purchasing an additional 122,634 shares during the last quarter. Finally, Dimensional Fund Advisors LP grew its holdings in shares of GlaxoSmithKline by 0.4% during the 3rd quarter. Dimensional Fund Advisors LP now owns 1,598,363 shares of the pharmaceutical company’s stock valued at $64,894,000 after purchasing an additional 5,759 shares during the last quarter. 10.98% of the stock is currently owned by hedge funds and other institutional investors.
Shares of GlaxoSmithKline plc (NYSE:GSK) opened at $37.65 on Tuesday. GlaxoSmithKline plc has a 1-year low of $34.52 and a 1-year high of $44.53. The company has a current ratio of 0.60, a quick ratio of 0.39 and a debt-to-equity ratio of 4.09. The firm has a market cap of $92,631.66, a P/E ratio of 47.66, a price-to-earnings-growth ratio of 2.27 and a beta of 0.95.
The firm also recently announced a quarterly dividend, which will be paid on Thursday, April 12th. Shareholders of record on Friday, February 23rd will be issued a dividend of $0.633 per share. This represents a $2.53 dividend on an annualized basis and a yield of 6.73%. This is a positive change from GlaxoSmithKline’s previous quarterly dividend of $0.50. The ex-dividend date is Thursday, February 22nd. GlaxoSmithKline’s payout ratio is presently 320.26%.
Several brokerages recently issued reports on GSK. Zacks Investment Research raised shares of GlaxoSmithKline from a “hold” rating to a “buy” rating and set a $41.00 price target on the stock in a report on Tuesday, March 6th. ValuEngine lowered shares of GlaxoSmithKline from a “buy” rating to a “hold” rating in a report on Friday, February 2nd. Kepler Capital Markets raised shares of GlaxoSmithKline from a “reduce” rating to a “hold” rating in a report on Friday, February 9th. JPMorgan Chase & Co. reaffirmed a “neutral” rating on shares of GlaxoSmithKline in a report on Monday, January 29th. Finally, TheStreet lowered shares of GlaxoSmithKline from a “b-” rating to a “c” rating in a report on Wednesday, February 7th. Two research analysts have rated the stock with a sell rating, nine have assigned a hold rating and five have given a buy rating to the company. GlaxoSmithKline currently has a consensus rating of “Hold” and an average target price of $38.77.
TRADEMARK VIOLATION WARNING: This piece of content was reported by Sports Perspectives and is the property of of Sports Perspectives. If you are reading this piece of content on another publication, it was stolen and republished in violation of U.S. and international trademark and copyright laws. The correct version of this piece of content can be viewed at https://sportsperspectives.com/2018/03/13/glaxosmithkline-plc-gsk-holdings-boosted-by-mackenzie-financial-corp.html.
GlaxoSmithKline plc is a global healthcare company. The Company operates through three segments: Pharmaceuticals, Vaccines and Consumer Healthcare. The Company focuses on its research across six areas: Respiratory diseases, human immunodeficiency virus (HIV)/infectious diseases, Vaccines, Immuno-inflammation, Oncology and Rare diseases.
Want to see what other hedge funds are holding GSK? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for GlaxoSmithKline plc (NYSE:GSK).
Receive News & Ratings for GlaxoSmithKline Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for GlaxoSmithKline and related companies with MarketBeat.com's FREE daily email newsletter.